Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Disease Progression × Fulvestrant × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 52 Neoplasm Metastasis 10 Neoplasms 4 Advanced Breast Cancer 4 Multiple Endocrine Neoplasia Type 1 2 Hereditary Sensory and Autonomic Neuropathies 2 Recurrence 1 Neoplasms by Site 1 HR-positive, HER2-negative Breast Neoplasms 1 Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer 1 Disease Progression 1 Carcinoma, Lobular 1 Carcinoma, Ductal, Breast 1 Breast Diseases 1

Interventions

Lenalidomide 3 capivasertib 2 Bortezomib 2 tivozanib 1 Zoledronic Acid 1 Vitamin D 1 Temozolomide 1 Radiotherapy 1 Nivolumab 1 Fulvestrant 1 Etoposide 1 Dexamethasone 1 Cisplatin 1 Carboplatin 1 Calcium Dobesilate 1 Calcium 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06635447 2026-01-13

CAPItrue

AstraZeneca

Phase 3 Recruiting

Breast Neoplasms, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon ⚡